Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 21 May 2024 for Innoviva, Inc., €3,980.
Insider track record
Disclosed buys
0
Disclosed sells
1
Signal history
Matthew Ronsheim: trading record in brief
Matthew Ronsheim, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Entasis Therapeutics Holdings Inc. and Innoviva, Inc. Over a trading history stretching from 15 January 2021 to 20 May 2024, the count stands at 11 filings.
Every open-market trade on record is a sale: 1 sale worth €10k. Other entries cover 8 share grants.
Most recently, on 21 May 2024, the filings show a share grant worth €3,980 in Innoviva, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Matthew Ronsheim
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
268 shares@ US$16.131.9% of flowCommon StockSEC:0000899140-24-000628:0
12,768 shares@ US$14.8881.6% of flowCommon StockSEC:0001104659-24-032002:0
807 shares@ US$15.805.5% of flowCommon StockSEC:0001104659-24-026716:0
1,600 shares@ US$16.0511.0% of flowCommon StockSEC:0000899140-24-000058:0
17,572 shares@ US$2.2080.3% of flowCommon StockSEC:0001104659-22-078801:0
125,000 shares0Common StockSEC:0001104659-22-005425:0
3,669 shares@ US$2.9419.7% of flowCommon StockSEC:0001104659-21-133635:0
25,000 shares0Common StockSEC:0001104659-21-128054:0
8 of 8 declarations
